Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chubb
McKesson
Johnson and Johnson
Daiichi Sankyo
US Department of Justice

Generated: August 21, 2019

DrugPatentWatch Database Preview

ZULRESSO Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Zulresso patents expire, and when can generic versions of Zulresso launch?

Zulresso is a drug marketed by Sage Therap and is included in one NDA. There are seven patents protecting this drug.

This drug has fifty-three patent family members in sixteen countries.

The generic ingredient in ZULRESSO is brexanolone. One supplier is listed for this compound. Additional details are available on the brexanolone profile page.

Drug patent expirations by year for ZULRESSO
Generic Entry Opportunity Date for ZULRESSO
Generic Entry Date for ZULRESSO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for ZULRESSO
(+)-3a-Hydroxy-5a-pregnan-20-one
(1S,2S,7S,11S,14S,15S,5R,10R)-14-acetyl-5-hydroxy-2,15-dimethyltetracyclo[8.7. 0.0<2,7>.0<11,15>]heptadecane
(3?,5?)-3-Hydroxy-pregnan-20-one
(3|A)-Allopregnanolone
(3a)-Allopregnanolone
(3alpha,5alpha)-3-hydroxypregnan-20-one
(3alpha)-Allopregnanolone
1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one
1-((3R,5S,8R,9S,10S,13S,14S,17S)-3-Hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone
1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
3-a-tetrahydroprogesterone
3-alpha-Hydroxy-5-alpha-pregnan-20-one
3-alpha-tetrahydroprogesterone
3-alpha,5-alpha-Pregnanolone
3-alpha,5-alpha-Tetrahydroprogesterone
3|A-hydroxy-5|A-pregnan-20-one
3|A-OH-DHP
3|A,5|A-THP
3a-Hydroxy-5a-dihydroprogesterone
3a-Hydroxy-5a-pregnan-20-one
3a-Hydroxy-5a-pregnane-20-one
3a,5a-Pregnanolone
3a,5a-Tetrahydroprogesterone
3a,5a-THP
3a,5a-THPROG
3alpha-Hydroxy-5alpha-20-one
3alpha-Hydroxy-5alpha-dihydroprogesterone
3alpha-hydroxy-5alpha-pregnan-20-one
3alpha-hydroxy-5alpha-pregnane-20-one
3alpha-OH DHP
3alpha,5alpha-tetrahydroprogesterone
3alpha,5alpha-THP
4-08-00-00664 (Beilstein Handbook Reference)
5-alpha-Pregnan-20-one, 3-alpha-hydroxy-
516-54-1
516A541
5a-Pregnan-3a-ol-20-one
5a-Pregnane-3a-ol-20-one
5alpha pregnan 3alpha ol 20 one
5alpha-Pregnan-3alpha-ol-20-one
5alpha-Pregnan-3alpha-ol-20-one, solid
5alpha-pregnane-3alpha-ol-20-one
8E5D696A-EEBC-495D-A8C9-98FC9A593150
AC-30353
AC1L3OU1
AKOS024285177
Allopregnalone
Allopregnan-3|A-ol-20-one
Allopregnan-3a-ol-20-one
Allopregnan-3alpha-ol-20-one
Allopregnanolone
Allotetrahydroprogesterone
AN-45490
AURFZBICLPNKBZ-SYBPFIFISA-N
B7456
BDBM50191342
BIDD:PXR0069
Biomol-NT_000266
BPBio1_000728
BRD-K18172896-001-01-7
brexanolona
Brexanolone
Brexanolone (USAN/INN)
Brexanolone [USAN]
brexanolonum
BRN 3211363
C13712
CAS-128-20-1
CHEBI:50169
CHEMBL207538
CS-6401
D11149
DB11859
DSSTox_CID_26342
DSSTox_GSID_46342
DSSTox_RID_81546
DTXSID1046342
EX-A1195
GTPL4108
HY-101107
LMST02030156
LS-118573
MFCD00003677
NCGC00163287-01
NCGC00163287-02
Pregnan-20-one, 3-hydroxy-, (3-alpha,5-alpha)-
Pregnan-20-one, 3-hydroxy-, (3-alpha,5-alpha)- (9CI)
Pregnan-20-one, 3-hydroxy-, (3a,5a)-
Pregnane-3alpha-ol-20-one, 5alpha-
Pregnanolone, (3alpha,5alpha)-isomer
S39XZ5QV8Y
SAGE-547
SAGE547
SCHEMBL588060
SGE-102
ST082264
Tox21_112042
UNII-S39XZ5QV8Y
ZINC4081043

US Patents and Regulatory Information for ZULRESSO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial Y   Try a Free Trial
Sage Therap ZULRESSO brexanolone SOLUTION;INTRAVENOUS 211371-001 Jun 17, 2019 RX Yes Yes   Try a Free Trial   Try a Free Trial   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
UBS
Mallinckrodt
Cantor Fitzgerald
Accenture
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.